{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:53:51Z","timestamp":1791060831564,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010264","name":"Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["GR004596"],"award-info":[{"award-number":["GR004596"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Glaucoma"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ogla.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:10:57Z","timestamp":1786947057000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of New Glaucoma Diagnosis and Surgery for Patients with Intravitreal Injections in the TriNetX Database"],"prefix":"10.1016","author":[{"given":"Shon B.","family":"Shmushkevich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-5754","authenticated-orcid":false,"given":"Sandi","family":"Bajrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6204-4538","authenticated-orcid":false,"given":"Zachary A.","family":"Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-0390","authenticated-orcid":false,"given":"Jonathan D.","family":"Tijerina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Basil K.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ogla.2026.08.002_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ogla.2026.08.002_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40942-021-00299-4","article-title":"Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab","volume":"7","author":"Hamid","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ogla.2026.08.002_bib3","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/s41433-022-02253-6","article-title":"Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration","volume":"37","author":"Siktberg","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.ogla.2026.08.002_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","article-title":"Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery","volume":"135","author":"Eadie","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.ogla.2026.08.002_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ogla.2026.08.002_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcjo.2021.06.025","article-title":"Incidence of ocular hypertension after anti-VEGF injections: examining the effect of drug filtration and silicone-free syringes","volume":"58","author":"Bae","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ophtha.2017.11.027","article-title":"The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry","volume":"125","author":"Atchison","year":"2018","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.ogla.2026.08.002_bib10","first-page":"4476","article-title":"Five- and ten-year glaucoma incidence in the Age-Related Eye Disease Study (AREDS)","volume":"53","author":"Joslin","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.08.002_bib11","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.2147\/OPTH.S482123","article-title":"The association of primary open angle glaucoma and ocular hypertension with anti-VEGF injections","volume":"18","author":"LoBue","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib12","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/OPTH.S232548","article-title":"Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration","volume":"13","author":"Wingard","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib13","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1167\/iovs.16-20786","article-title":"Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration","volume":"58","author":"Wen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.08.002_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1167\/iovs.16-20779","article-title":"VEGF as a paracrine regulator of conventional outflow facility","volume":"58","author":"Reina-Torres","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ogla.2026.08.002_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2020.12.016","article-title":"Rates of RNFL thinning in patients with suspected or confirmed glaucoma receiving unilateral intravitreal injections for exudative AMD","volume":"226","author":"Swaminathan","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41433-018-0148-6","article-title":"Effect of age on the morphologies of the human Schlemm's canal and trabecular meshwork measured with swept-source optical coherence tomography","volume":"32","author":"Chen","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.ogla.2026.08.002_bib17","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/IAE.0000000000001018","article-title":"Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections","volume":"36","author":"Wen","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ogla.2026.08.002_bib18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ogla.2026.08.002_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ophtha.2005.10.061","article-title":"Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide","volume":"113","author":"Benz","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ogla.2026.08.002_bib20","series-title":"Medical Retina. Essentials in Ophthalmology","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-33672-3_5","article-title":"Intravitreal injections: techniques and sequelae","author":"Heimann","year":"2007"},{"key":"10.1016\/j.ogla.2026.08.002_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ogla.2020.04.005","article-title":"Recurrent tube erosions with anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"3","author":"Liu","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2026.08.002_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ogla.2024.01.002","article-title":"Glaucoma tube outcomes with and without anti-VEGF in patients with age-related macular degeneration","volume":"7","author":"Rothman","year":"2024","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ogla.2026.08.002_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/aes-24-27","article-title":"A narrative review of TriNetX in ophthalmology: applications, advantages, and pitfalls","volume":"9","author":"Hackl","year":"2024","journal-title":"Ann Eye Sci"}],"container-title":["Ophthalmology Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626001353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589419626001353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:11:23Z","timestamp":1791058283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589419626001353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"alternative-id":["S2589419626001353"],"URL":"https:\/\/doi.org\/10.1016\/j.ogla.2026.08.002","relation":{},"ISSN":["2589-4196"],"issn-type":[{"value":"2589-4196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of New Glaucoma Diagnosis and Surgery for Patients with Intravitreal Injections in the TriNetX Database","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Glaucoma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ogla.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}